RESEARCH MONOGRAPH · KDC-MN-066

Meldonium (Mildronate)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

67/100

Carnitine biosynthesis inhibitor with real exercise-physiology mechanism, more interesting than the doping headlines suggest

Look, everyone knows meldonium as the thing Sharapova tested positive for in 2016, and that ended up overshadowing what's actually a clever piece of medicinal chemistry. Ivars Kalvins designed this at the Latvian Institute of Organic Synthesis in the 70s as a gamma-butyrobetaine analog, and the mechanism is genuinely elegant: it competitively inhibits gamma-butyrobetaine hydroxylase (BBOX1), the rate-limiting enzyme of carnitine biosynthesis.

Drop carnitine availability and you force the cell to shift away from fatty acid oxidation toward glucose oxidation. In ischemic tissue, that's actually protective because glucose oxidation is more oxygen-efficient per ATP than beta-oxidation when oxygen is limiting. Thats the cardiology indication and the rationale behind the Russian and Baltic clinical use for stable angina.

What we like is the carnitine shuttle biology. Meldonium is one of the only readily available research-grade BBOX1 inhibitors, which makes it useful for studying carnitine-dependent metabolism in cell culture and animal models. The pharmacokinetics are also unusually clean (small molecule, good oral bioavailability, predictable plasma curves), and the safety profile from 30+ years of Latvian and Russian clinical use is reassuring.

What we dont like: the human evidence for the broader indications (cognition, fatigue, exercise performance) is much thinner than the marketing suggests. WADA banned it because some athletes were clearly using it, but the actual ergogenic effect size is contested. The Latvian trials are mostly small and not always blinded, and the western literature is sparse.

Sourcing is mostly fine. The molecule is simple enough that pure material is straightforward at HPLC scale, though there are some persistent reports of underdosed Russian pharmaceutical lots. For research use, stick to vendors that publish purity data.

For studying carnitine biology, hypoxia tolerance, or substrate-switching in metabolic models, meldonium is genuinely useful. As a generic performance compound, the evidence base doesnt match the reputation. The mechanism story is the part worth keeping.

Evidence: 55
Mechanism: 80
Reliability: 65
Safety: 78
Sourcing: 72
Value: 70
Signal: 60
Staying power: 60

Plain-language summary Intrigue 68 / 100

Meldonium (Mildronate) is a Latvian-developed compound that inhibits carnitine biosynthesis, shifting cellular metabolism toward glucose-based energy. It is used for ischemic conditions in Eastern Europe. Famous for the 2016 Maria Sharapova doping case. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Carnitine biosynthesis inhibitor

A Latvian-developed carnitine biosynthesis inhibitor used clinically for ischemic heart disease, banned by WADA in 2016 after high-profile athlete cases.

Abstract

Meldonium (Mildronate; 3-(2,2,2-trimethylhydrazinium)propionate; CAS 76144-81-5; molecular formula C6H14N2O2; molecular weight 146.19) is a synthetic structural analog of gamma-butyrobetaine, the precursor of L-carnitine, developed at the Latvian Institute of Organic Synthesis in the 1970s by Ivars Kalvins. The compound competitively inhibits gamma-butyrobetaine hydroxylase, reducing endogenous carnitine biosynthesis and shifting cardiac and skeletal muscle metabolism from fatty acid oxidation toward glucose oxidation. The metabolic shift is theoretically protective under ischemic conditions where fatty acid oxidation generates increased reactive oxygen species. Meldonium is approved in Latvia, Russia, and several former Soviet states for ischemic heart disease, chronic heart failure, and cognitive symptoms of cerebrovascular insufficiency. The compound was added to the WADA prohibited list in 2016 after widespread use in elite athletes; the Maria Sharapova case is the most prominent. Pharmacokinetics: plasma half-life 3 to 6 hours; oral bioavailability 78 percent; renally excreted. Reported research dose ranges in the literature are described in the source monograph.

Mechanism of action

Competitive inhibition of gamma-butyrobetaine hydroxylase, reducing carnitine biosynthesis. Shifts cardiac/skeletal metabolism from fatty acid to glucose oxidation.

Reported research dose ranges

500 to 1000 mg (reported research dose range).

References

Dambrova M, et al. Mildronate: cardioprotective action through carnitine-lowering effect. Trends Cardiovasc Med 2002.
Schobersberger W, et al. Meldonium: prevalence in elite athletes and pharmacology. Drug Test Anal 2017.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-066

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Meldonium (Mildronate)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs